To­tus pulls in $40M Se­ries A with sights on PI3Kα; FDA asks Sesen for an­oth­er tri­al af­ter CRL, biotech says

Af­ter spend­ing the last 18 months work­ing on iden­ti­fy­ing a lead can­cer drug, biotech start­up To­tus Med­i­cines has now raised $40 mil­lion in a Se­ries A round to get the ther­a­py head­ed to the clin­ic.

The biotech isn’t hold­ing any­thing back in its re­lease, tout­ing its “rev­o­lu­tion­ary” plat­form ap­proach and prospects in a high­ly com­pet­i­tive field. Their orig­i­nal tar­get is PI3Kα.

CEO Neil Dhawan says:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.